Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients

Annals of Clinical and Translational Neurology

Volumn 2, Issue 4, 2015, Pages 362-372

  Bruneteau, Gaëlle ^a,b   Bauché, Stéphanie ^a   De Aguilar, Jose Luis Gonzalez ^c,d   Brochier, Guy ^b   Mandjee, Nathalie ^a   Tanguy, Marie Laure ^b   Hussain, Ghulam ^c,d   Behin, Anthony ^b   Khiami, Frédéric ^b   Sariali, Elhadi ^b   Hell Remy, Caroline ^b   Salachas, François ^b   Pradat, Pierre François ^b   Lacomblez, Lucette ^b   Nicole, Sophie ^a   Fontaine, Bertrand ^a   Fardeau, Michel ^b   Loeffler, Jean Philippe ^c,d   Meininger, Vincent ^b   Fournier, Emmanuel ^a,b   Koenig, Jeanine ^a   Hantaï, Daniel ^a,b   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d Laboratoire des Mecanismes Centraux et Peripheriques de la Neurodegenerescence   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928069440     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/ACN3.179     Document Type: Article

References (40)

1. Charcot JM, Joffroy A. Deux cas d’atrophie musculaire progressive avec lésions de la substance grise et des faisceaux antéro-latéraux de la moelle épiniére. Arch Physiol 2015;2:362-372.
2. Beghi E, Mennini T, Bendotti C, et al. The heterogeneity of amyotrophic lateral sclerosis: A possible explanation of treatment failure. Curr Med Chem 2007;14:3185-3200.
3. Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp Neurol 2004;185:232-240.
4. Vinsant S, Mansfield C, Jimenez-Moreno R, et al. Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: Part II, results and discussion. Brain Behav 2013;3:431-457.
5. Frey D, Schneider C, Xu L, et al. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 2000;20:2534-2542.
6. Pun S, Santos AF, Saxena S, et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 2006;9:408-419.
7. Jokic N, Gonzalez de Aguilar JL, Pradat PF, et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005;57:553-556.
8. Dupuis L, Gonzalez de Aguilar JL, di Scala F, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:358-365.
9. Jokic N, Gonzalez de Aguilar JL, Dimou L, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 2006;7:1162-1167.
10. Denys EH, Norris FH Jr. Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission. Arch Neurol 1979;36:202-205.
11. Henderson R, Baumann F, Hutchinson N, McCombe P. CMAP decrement in ALS. Muscle Nerve 2009;39:555-556.
12. Killian JM, Wilfong AA, Burnett L, et al. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve 1994;17:747-754.
13. Wang FC, De Pasqua V, Gerard P, Delwaide PJ. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients. Neurology 2001;57:897-899.
14. Yamashita S, Sakaguchi H, Mori A, et al. Significant CMAP decrement by repetitive nerve stimulation is more frequent in median than ulnar nerves of patients with amyotrophic lateral sclerosis. Muscle Nerve 2012;45:426-428.
15. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
16. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRSR: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
17. AAEM. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Summary statement. Muscle Nerve 2001;24:1236-1238.
18. Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004;56:650-661.
19. Maselli RA, Mass DP, Distad BJ, Richman DP. Anconeus muscle: A human muscle preparation suitable for in-vitro microelectrode studies. Muscle Nerve 1991;14:1189-1192.
20. Maselli RA, Wollman RL, Leung C, et al. Neuromuscular transmission in amyotrophic lateral sclerosis. Muscle Nerve 1993;16:1193-1203.
21. Koelle GB, Friedenwald JA. A histochemical method for localizing cholinesterase activity. Proc Soc Exp Biol Med 1949;70:617-622.
22. Romero-Calvo I, Ocon B, Martinez-Moya P, et al. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem 2010;401:318-320.
23. Mateen FJ, Carone M, Sorenson EJ. Patients who survive 5 years or more with ALS in Olmsted County, 1925-2004. J Neurol Neurosurg Psychiatry 2010;81: 1144-1146.
24. Bjornskov EK, Dekker NP, Norris FH Jr, Stuart ME. Endplate morphology in amyotrophic lateral sclerosis. Arch Neurol 1975;32:711-712.
25. Tsujihata M, Hazama R, Yoshimura T, et al. The motor end-plate fine structure and ultrastructural localization of acetylcholine receptors in amyotrophic lateral sclerosis. Muscle Nerve 1984;7:243-249.
26. Yoshihara T, Ishii T, Iwata M, Nomoto M. Ultrastructural and histochemical study of the motor end plates of the intrinsic laryngeal muscles in amyotrophic lateral sclerosis. Ultrastruct Pathol 1998;22:121-126.
27. Grady RM, Akaaboune M, Cohen AL, et al. Tyrosinephosphorylated and nonphosphorylated isoforms of alphadystrobrevin: Roles in skeletal muscle and its neuromuscular and myotendinous junctions. J Cell Biol 2003;160:741-752.
28. Schmidt N, Akaaboune M, Gajendran N, et al. Neuregulin/ErbB regulate neuromuscular junction development by phosphorylation of alpha-dystrobrevin. J Cell Biol 2011;195:1171-1184.
29. Couteaux R, Mira JC, d’Albis A. Regeneration of muscles after cardiotoxin injury. I. Cytological aspects. Biol Cell 1988;62:171-182.
30. Meriggioli MN, Howard JFJ, Harper CMJ. Pathophysiology of neuromuscular junction disorders. In: Dekker M, ed. Neuromuscular junction disorders: Diagnosis and treatment. New York: CRC Press, 2003: Pp 37-57.
31. Son YJ, Thompson WJ. Nerve sprouting in muscle is induced and guided by processes extended by Schwann cells. Neuron 1995;14:133-141.
32. O’Malley JP, Waran MT, Balice-Gordon RJ. In vivo observations of terminal Schwann cells at normal, denervated, and reinnervated mouse neuromuscular junctions. J Neurobiol 1999;38:270-286.
33. Coers C. Histological aspects of neuromuscular regeneration during various diseases of the peripheral motor neuron; collateral regeneration in humans. Acta Neurol Psychiatr Belg 1955;55:23-30.
34. Wohlfart G. Collateral regeneration from residual motor nerve fibers in amyotrophic lateral sclerosis. Neurology 1957;7:124-134.
35. Fardeau M. Simultaneous staining of the terminal motor innervation and the sub-neural apparatus (S. Manolov’s technic). Importance for diagnosis in neuro-muscular pathology. Rev Neurol (Paris) 1964;111:501-506.
36. O’Neill JH, Murray NM, Newsom-Davis J. The Lambert- Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111(Pt 3):577-596.
37. Stalberg E. Electrophysiological studies of reinnervation in ALS. Adv Neurol 1982;36:47-59.
38. Maselli RA, Arredondo J, Ferns MJ, Wollmann RL. Synaptic basal lamina-associated congenital myasthenic syndromes. Ann N Y Acad Sci 2012;1275:36-48.
39. Patton BL, Chiu AY, Sanes JR. Synaptic laminin prevents glial entry into the synaptic cleft. Nature 1998;393:698-701.
40. Bros-Facer V, Krull D, Taylor A, et al. Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 2014;23:4187-4200.